Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2013 Jul 26;12(10):2200–2212. doi: 10.1158/1535-7163.MCT-13-0095

Figure 6.

Figure 6

Combination of erlotinib and niclosamide overcomes acquired erlotinib resistance in vivo. A, Mice bearing HCC827 or HCC827/ER lung cancer xenografts were treated with vehicle control, erlotinib (Erlo, 40mg/kg/d), niclosamide (Niclo, 20mg/kg/d) or their combination for 32 days. Each group includes 8 mice. Tumor volume was measured once every 2 days. After 32 days, the mice were sacrificed and the tumors were removed and analyzed. Representative tumor pictures were taken. B, Active caspase 3 was analyzed in tumor tissues at the end of experiments by IHC staining and quantified as described in “Methods”. C, Expression levels of pEGFR, pSTAT3, Bcl2 and Bcl-XL from tumor tissues in various treatment groups were analyzed by Western blot.